Trials / No Longer Available
No Longer AvailableNCT03529539
Expanded Access for PSV Personalized Oncolytic Viruses
- Status
- No Longer Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- EpicentRx, Inc. · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- —
Summary
A compassionate use, expanded access protocol for patients who have exhausted all standard therapy having progressed on chemotherapy and immunotherapy.
Detailed description
Patients will receive intratumoral or subcutaneous injection of an oncolytic virus called PSV (short for Personalized Virus) every other week until the occurrence of immune related RECIST progression, intolerable toxicity, change to another anti-cancer treatment due to lack of apparent benefit, or personal choice.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PSV |
Timeline
- First posted
- 2018-05-18
- Last updated
- 2019-03-06
Source: ClinicalTrials.gov record NCT03529539. Inclusion in this directory is not an endorsement.